

A Multidisciplinary Indexed International Research Journal

ISSN: 23203714

Volume : 7



ADHYAYAN  
INTERNATIONAL  
RESEARCH  
ORGANISATION

## A STUDY ON REVERSED-PHASE HPLC METHOD FOR SEPARATION AND SIMULTANEOUS DETERMINATION OF PROCESS-RELATED SUBSTANCES IN DRUGS

Tauseef Ahmad Siddiqi

Research Scholar Sri Venkateshwara University Gajraula, U.P

### Abstract

*A simple and rapid reversed-phase high-performance liquid chromatographic method has been developed for the separation and simultaneous determination of related substances of mirtazapine in bulk drugs and pharmaceutical formulations. Six impurities, including one degradation product of mirtazapine, have been separated on a BDS Hypersil (4.6 × 250 mm; particle size 5 μm) column with a mobile phase consisting of 0.3% triethylamine (pH 3.0)–acetonitrile (78:22 v/v) eluted in an isocratic mode and monitored with a photo diode array detector at 215 nm. The chromatographic behavior of all the analytes was studied under variable compositions of different solvent systems, temperatures, buffer concentrations, and pH values. The method was validated in terms of accuracy, precision, and linearity. The inter- and intra-day assay precision was found to be < 0.98% [relative standard deviation; (RSD)] and the recoveries were in the range 95.54–102.22% with RSD < 2.21%. The correlation coefficients for calibration curves for mirtazapine as well as impurities were in the range of 0.9941–0.9999. The method was successfully applied to the analysis of commercial formulations and the recoveries of mirtazapine were in the range of 99.38–100.73% with < 0.52% RSD. The method is useful not only for rapid evaluation of the purity of mirtazapine, but also for the simultaneous determination of related substances in bulk drugs and pharmaceutical formulations.*

### Introduction

Mirtazapine, 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a]-pyrido [2,3-c][2] benzazepine, is a tetracyclic antidepressant used in the treatment of patients with severe depression (1). It is a member of the piperazinoazepines, structurally not related to any known class of psychotropic drugs. It has

a unique pharmacological profile combining dual action on both the noradrenergic and serotonergic neurotransmitter systems by blocking  $\alpha_2$  receptors and selectively antagonizing 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors (2). Mirtazapine is extensively metabolized by the liver, and the biotransformations include

## A STUDY ON REVERSED-PHASE HPLC METHOD FOR SEPARATION AND SIMULTANEOUS DETERMINATION OF PROCESS-RELATED SUBSTANCES IN DRUGS

hydroxylation, demethylation, oxidation, and conjugation with sulphate or glu-curonic acid (3). Des-methylmirtazapine, is a pharmacologically active metabolite which contributes 3–6% of the total pharmacodynamic profile of mirtazapine (4). While studying the syn-thetic process in our laboratory, we observed I, II, III, IV, and VI (Figure 1) as process-related impurities likely to be present in the finished products. Thus, there is a great need for develop-ment of analytical methods for separation and determination of related substances not only for evaluation of quality of mirtaza-pine but also pharmacological profiles for clinical studies.

Several methods have been described in the literature for the determination of mirtazapine and demethylmirtazapine in biological fluids. The techniques used include capillary electrophoresis (5), gas chromatography (6,7), and high-perfor- array (10,11), tandem mass spectrometry (12), and fluorimetry (13–15). Recently, HPLC with UV detection has been used for the separation of enantiomers of mirtazapine in human plasma (16–18). Spectrometric and spectrofluorimetric methods have been used for the determination of mirtazapine in pharma-ceutical formulations (19,20). Wynia et al. have developed a capillary zone electrophoresis

method for the determination of mirtazapine and five of its structurally related substances in pharmaceutical dosage forms, and compared the results with those obtained by HPLC using an ion pair reagent as a mobile phase additive (21). The use of ion pair reagents in the mobile phase decreases the column life and needs a long time for equilibration. Furthermore, the method was not validated thoroughly.

This paper describes a reversed-phase (RP) isocratic HPLC method for the simultaneous separation and determination of mirtazapine, degradation products, and process related impuri-ties on a C<sub>18</sub> column using triethylamine (TEA) (pH adjusted to 3 with H<sub>3</sub>PO<sub>4</sub>) and acetonitrile as a mobile phase. The method was validated and found to be suitable for the quality assessment of mirtazapine in pharmaceutical formulations in the presence of process-related impurities and degradation products. Forced degradation of mirtazapine was carried out under thermal, photo, and acidic, basic, and peroxide conditions. performance liquid chromatography (HPLC) with UV (8,9), diode-




Figure 1. Process-related impurities (I, II, III), side products (IV and VI), and degradation product (VI) of mirtazapine (V).

## Experimental

### Materials and reagents

All reagents were of analytical-reagent grade unless stated otherwise. Glass-distilled and de-ionized water (Barnstead Nanopure, Thermo Fisher; Waltham, MA), HPLC-grade acetonitrile, methanol, triethylamine, and orthophosphoric acid (S.D. Fine Chem; Mumbai, India) were used. The investigated samples of mirtazapine bulk drug materials and impurities were obtained from the process development department of IICT (Hyderabad, India).

### Apparatus

The HPLC system was composed of two LC-10AT VP pumps, an SPD-M10AVP photo diode array detector, an SIL-10AD VP auto injector, a DGU-12A degasser, an SCL-10A VP system controller, and CTD-6AS

column oven (all from Shimadzu, Kyoto, Japan). An RP BDS Hypersil C<sub>18</sub> (250 × 4.6 mm i.d; particle size 5 μm) column (Thermo Electron Corporation, Reading, U.K.) was used for separation. The chromatographic and the integrated data were recorded using an HP-Vectra (Hewlett Packard, Waldbronn, Germany) computer system.

### Chromatographic conditions

The analysis was carried out on a BDS Hypersil C<sub>18</sub> column using a mobile phase consisting of 0.3% TEA (pH adjusted to 3.0 with ortho-phosphoric acid) and acetonitrile in the ratio (78:22 v/v). Before delivering the mobile phase into the system, the solvent was degassed and filtered through 0.45 μm PTFE filter using 20 μL. The detection was performed at 215 nm using a photo-diode array detector (PDA).

### Analytical procedures

Stock solutions (1000 μg/mL) of mirtazapine and its process impurities were prepared by dissolving known amounts of the components in the mobile phase. The solutions were adequately diluted to determine the accuracy, precision, linearity, and limits of detection and quantitation (LOD and LOQ). The specific concentration of mirtazapine was taken as 100 μg/mL.

## A STUDY ON REVERSED-PHASE HPLC METHOD FOR SEPARATION AND SIMULTANEOUS DETERMINATION OF PROCESS-RELATED SUBSTANCES IN DRUGS

### **Preparation of drug matrix and formulation solutions**

An excipient matrix containing starch, methylcellulose, calcium phosphate, and calcium carbonate in the ratio 1:1:1:1 (w/w/w/w) was prepared. It (100 mg) was transferred to a 100-mL volumetric flask and dissolved in methanol. It was fortified with mirtazapine (1000 µg/mL), ultra-sonicated for approximately 10 min, and made up to the mark with the mobile phase. The supernatant liquid was collected and filtered through a 0.45-micron filter for use. The solution was adequately diluted to determine the accuracy, precision, and LOD and LOQ of mirtazapine. The solutions of mirtazapine formulation were prepared in a similar way. Ten weighed tablets of mirtazapine were finely powdered and homogenized in a mortar. An amount equivalent to 200 mg of mirtazapine was taken into a 100-mL volumetric flask, dissolved in methanol, ultra-sonicated for approximately 10 min, and made up to the mark with the mobile phase. The supernatant liquid was collected and filtered through a 0.45-micron filter for use.

### **Method validation**

The developed method was validated with respect to specificity, accuracy, precision, and linearity.

### *Specificity*

Specificity is the ability of the method to measure the analyte response in the presence of all potential impurities. For specificity determination, all known impurities were added to mirtazapine and its concentration was determined using the developed method. The specificity was also checked by stressing mirtazapine under (i) UV light at 254 nm and 60°C temperature for 15 days, and (ii) extreme conditions such as 1N HCl, 1N NaOH, and 3% H<sub>2</sub>O<sub>2</sub>. Interference of excipients was studied by spiking a known amount of mirtazapine into matrix solution, and extracted in methanol, and the recovery was measured by the developed method.

### *Accuracy*

Accuracy of the method was performed by recovery experiments using standard addition technique. The recoveries of I, II, III, IV, and VI were determined by spiking each impurity at five different levels ranging from 0.5–2.0 µg/mL into mirtazapine formulation solution, extracting into methanol, and using them for recovery studies. Similarly, recovery studies were carried out for mirtazapine by fortifying mirtazapine bulk drug solution with matrix solution at five concentration levels (i.e., 50, 75, 100, 120, and 150 µg/mL) in triplicate for 3 days. The extraction of

fortified drug matrix was carried out as described under the "Preparation of drug matrix and formulation solutions" section.

### *Precision*

The fortified drug matrix solution was prepared at different concentrations of mirtazapine, and precision of the method was studied using repeatability, intermediate precision, and reproducibility (ruggedness). Repeatability was the intra-day variation in assay obtained at different concentration levels of mirtazapine and expressed in terms of relative standard deviation (RSD) calculated for each day. The intermediate precision was the inter-day variation at the same concentration level determined on successive days. The ruggedness of the method was defined as the degree of reproducibility obtained by the analysis of the same sample under a variety of conditions at different labs, with different analysts using different instruments and different lots of reagents.

### *Linearity*

The linearity of detector response to different concentrations of impurities was studied in the range from 0.5–5.0 µg/mL. Similarly, the linearity of mirtazapine was also studied by preparing standard solutions at ten different levels ranging from 25 to 200

µg/mL. The data were subjected to statistical analysis using a linear-regression model.

### **LOD and LOQ**

LOD and LOQ represent the concentration of the analyte that would yield signal-to-noise ratios of 3 for LOD and 10 for LOQ, respectively. LOD and LOQ were determined by measuring the magnitude of analytical background, by injecting matrix solution and calculating the signal-to-noise ratio for each compound by injecting a series of solutions until the S/N ratio reached 3 for LOD and 10 for LOQ.

### **Method development**

All impurities and mirtazapine were subjected to separation by RP-HPLC on different commercial C<sub>18</sub> columns. Initially, buffers such as acetate and phosphate were tried using methanol and acetonitrile as organic modifiers. However, the compounds exhibited a characteristic tailing on all columns. This could be due to their ability to form strong hydrogen bonding with the residual silanols of the C<sub>18</sub> materials. To minimize the tailing and to improve peak shapes, TEA in the range 0.1%–0.3% (concentration) was used as a buffering system. The effect of pH (6.0–3.0) of the buffer on separation was studied. To minimize the peak tailing, the column

**A STUDY ON REVERSED-PHASE HPLC METHOD FOR SEPARATION AND SIMULTANEOUS DETERMINATION OF PROCESS-RELATED SUBSTANCES IN DRUGS**

temperature was increased (25°C–40°C). Among the studied columns, BDS Hypersil C<sub>18</sub> (250 mm × 4.6 mm) had shown promising separation of the test compounds with minimum tailing, so it was chosen for method development.

**Results and Discussion**

The chemical structures of all compounds are shown in Figure 1. The present study was aimed at developing a chromatographic system capable of eluting and resolving mirtazapine and its impurities.

**Optimization of the chromatographic conditions**

The HPLC conditions were optimized by studying the effects of concentration of organic modifier, concentration of TEA, buffer pH, and column temperature.

**Effect of organic modifier**

Methanol and acetonitrile were tried as organic modifiers with TEA buffer (pH = 3.0) on a BDS Hypersil C<sub>18</sub> (250 mm × 4.6 mm) column maintained at 40°C. With methanol, compounds were eluted at higher retention times with broad peak shapes, while with acetonitrile, sharp peaks were found. So acetonitrile was selected as organic modifier.

Further studies were carried out to

determine the effect of acetonitrile concentration on separation of the test compounds. The effect of acetonitrile on retention and resolution is given in Table I. From Table I, it can be clearly seen that as the concentration of acetonitrile decreased, the resolutions and retentions increased, but peaks became broad. At 22% of acetonitrile, optimum resolutions were found, with sharp and symmetrical peaks.

**Table I. The Effect of Organic Modifier on Resolution and Retention Factors in Optimized Conditions**

Organic modifier (%)	Retention factor (k)						Resolution (R <sub>s</sub> )					
	I	II	III	IV	V	VI	I	II	III	IV	V	VI
25	0.11	0.38	0.47	1.32	1.53	1.89	3.50	1.61	10.76	1.67	2.12	–
22	0.13	0.46	0.61	1.84	2.13	2.59	5.42	2.43	12.52	1.92	2.47	–
20	0.16	0.76	1.00	2.99	3.37	4.01	7.82	3.12	16.72	2.13	2.94	–

**Table II. The Effect of TEA and Temperature on Resolution and Tailing in Optimized Conditions**

TEA (%)	Temperature (°C)	Resolution ( $R_s$ )						Tailing factor ( $A_s$ )					
		I	II	III	IV	V	VI	I	II	III	IV	V	VI
0.1	40	3.91	5.15	15.67	1.14	1.57	-		1.21	1.17	1.25	1.31	2.64
2.55													
0.2	40	5.92	2.89	14.49	1.47	2.46	-		1.20	1.17	1.23	1.21	2.07
1.69													
0.3	40	5.42	2.43	12.52	1.92	2.47	-	1.13	1.17	1.15	1.27	1.55	1.35
0.3	25	5.91	2.22	12.76	2.13	2.59	-	1.08	1.21	1.32	1.71	2.21	1.71
0.3	30	5.79	2.27	12.66	2.08	2.55	-		1.09	1.21	1.26	1.59	1.87

### Concentration of TEA

The effect of TEA buffer concentration on the system was studied by varying its concentration from 0.1% to 0.3%. The pH of the buffer was adjusted to 3.0 with diluted  $H_3PO_4$ , and the BDS Hypersil  $C_{18}$  column was maintained at 40°C. As the concentration of TEA increased, retentions decreased (Figure 2A). But resolution was increased for (I, II), (IV, V), and (V, VI) and decreased for (II, III) and (III, IV) (Table II). Tailing was reduced (Table II) with improved peak shapes by increasing the concentration of TEA. At 0.3% of TEA, sharp symmetrical peaks with good resolution were obtained. So 0.3% of TEA was used for further optimization of other variables. The tailing of the mirtazapine peak compared to other peaks was higher, probably due to its higher concentration.

### Effect of pH

Further studies were carried out to determine the effect of buffer pH on resolution and retention. On increasing the pH, retention of test compounds was increased (Figure 2B) and it was more for compounds III, IV, V, and VI. At pH 5.0 to 6.0, compounds I and II were co-eluted and V was eluted after VI. On decreasing the pH, resolution increased for I and II and decreased for other compounds (Table III). But with a decrease in pH, peaks became sharp and tailing was reduced drastically for all compounds (Table III), allowing accurate quantitation. At pH 3.0, symmetrical peaks with optimum resolutions were obtained.


### Effect of temperature

The column was maintained at different temperatures ranging from 25°C–40°C in a thermostated oven. Retention times decreased slightly with increasing temperature, but

**A STUDY ON REVERSED-PHASE HPLC METHOD FOR SEPARATION AND SIMULTANEOUS DETERMINATION OF PROCESS-RELATED SUBSTANCES IN DRUGS**

peaks became very sharp, and resolutions increased for compounds II and III and slightly decreased for the remaining compounds. PDA detector set at 215 nm. These were the final optimized conditions. A typical chromatogram of mirtazapine (V) spiked with 5% (w/w) of each of the related substances is shown in Figure 3. It is clear from Figure 3 that all compounds were eluted and separated with good peak shapes and resolution. The method was applied to pharmaceutical formulations. The HPLC chromatogram of a typical formulation is shown in Figure 4. The peaks were identified by injecting and comparing with the retention times of the individual compounds and also by the absorption spectra recorded by the PDA detector. Unknown impurity UK1 and excipients (EX1) in the formulations were well-separated under the optimized conditions (Figure 4). A monograph of mirtazapine was recently approved by the European Pharmacopeia (E.P.) of 2007. It describes a method that utilizes a mobile phase comprising of a very high concentration of tetramethyl ammonium hydroxide as a buffer and tetrahydrofuran, methanol, and acetonitrile as organic modifiers for separation of related substances. The use of high concentrations of such ion pair reagents decreases the column lifetime and needs a long time for equilibrium. Furthermore, the

present work describes a method for the separation of six impurities, including two new substances which were not reported by the E.P. Moreover, the run time of the present method was half of that of the E.P., and the detection limits of mirtazapine and impurities were quite low compared to E.P.



**Table IV. Specificity Data**

S. No.	Assay of mirtazapine (%)	
	Without spiking the impurities	Spiked with impurities
1	99.97	99.96
2	99.92	99.83
3	99.86	99.85
Mean	99.92	99.86
SD	0.055	0.068
RSD	0.055	0.068

**Table V. System Suitability Data\***

Sample	$t_R (\pm RSD)^\dagger$		$R_s$	$A_t$	RRF
	(min)	RRT			
I	3.49 ± 0.08	0.371	5.42	1.08	0.29
II	4.38 ± 0.18	0.466	2.43	1.17	0.65
III	4.83 ± 0.14	0.514	12.52	1.15	0.39
IV	8.53 ± 0.21	0.907	1.92	1.22	0.85
V	9.40 ± 0.25	1.00	2.47	1.55	1.00
VI	10.79 ± 0.28	1.148	—	1.35	0.47

\* Abbreviations:  $t_R$ , retention time; RRT, relative retention time;  $R_s$ , resolution;  $A_t$ , tailing factor; RRF, relative response factor; RSD, relative standard deviation.  
<sup>†</sup> Average of five determinations.

**Table III. The Effect of pH on Resolution and Tailing in Optimized Conditions**

pH	Resolution ( $R_s$ )						Tailing factor ( $A_s$ )					
	I	II	III	IV	V	VI	I	II	III	IV	V	VI
3	5.42	2.43	12.52	1.92	2.47	–	1.13	1.17	1.15	1.27	1.55	1.35
4	0.51	6.92	13.39	6.40	6.84	–	1.07	1.19	1.25	1.59	1.88	1.72
5	0.00	10.45	11.40	3.34	9.95	–	1.09	1.21	1.39	2.10	2.36	2.17


(Table II). But tailing was reduced with increasing temperature for IV, V, and VI; at 40°C, minimum tailing was found. Finally, separation was carried out on a BDS Hypersil C<sub>18</sub> (250 mm · 4.6 mm) column maintained at 40°C using a mobile phase con-sisting of 0.3% TEA (pH = 3.0) and acetonitrile (78:22 v/v) with

**Validation**

*Specificity*

Specificity was performed by spiking impuri-ties into mirtazapine, and the assay results for mirtazapine were not changed in the presence of impurities (Table IV). Stressed degradation studies were also carried out to check the speci-ficity of the method with respect to degradation products. Under UV light, thermal, acidic, and alkaline conditions, no change in the sample purity was observed; but in the presence of peroxide, one degraded product was formed, was well-separated from mirtazapine, and matched with impurity VI in the present conditions (Figure 3). The recov-eries for the mirtazapine fortified drug matrix solutions were in the range 99.31%–100.75%, indicating specificity of the method with respect to matrix solutions. In pharmaceutical formula-tions, it was observed that the excipient peaks did not interfere with the peaks of interest (Figure 4), and excipients (EX1) and unknown

impurity (UK1) were well-separated from mirtazapine and other impurities



**Figure 3.** Typical chromatograms of mirtazapine (V) spiked with 5% (w/w) each of the impurities (I, II, III, IV, and VI); degradation of mirtazapine (V) with H<sub>2</sub>O<sub>2</sub> (B).

*System suitability*

The system suitability was conducted using 1.0% (w/w) of all the impurities spiked into mirtazapine (100 µg/mL) and evalu-ated by making five replicate injections. The system was suitable for use if

**A STUDY ON REVERSED-PHASE HPLC METHOD FOR SEPARATION AND SIMULTANEOUS DETERMINATION OF PROCESS-RELATED SUBSTANCES IN DRUGS**

the tailing factors for mirtazapine and its impurities were not more than 1.55 and the resolution was not less than 1.92. Synthetic mixtures and process samples were analyzed under identical conditions. The quantities of impurities and assay of V were calculated from their respective peak areas. System suitability data is given in Table V.

*Accuracy*

The recoveries of I, II, III, IV, and VI were determined by spiking each impurity at five different levels ranging from 0.5–2.0 µg/mL into mirtazapine formulation solution at the specified level (100 µg/mL). The recovery range and RSD for all impurities were found to be 95.54–102.22% and 0.33–2.21%, respectively (Table VI). Similarly, the recovery studies for mir-tazapine were carried out by fortifying drug solutions at five concentration levels each (i.e., 50, 75, 100, 120, and 150 µg/mL) in triplicate for 3 days and recording the percentage recoveries in Table VI. The RSD values were found to be below 0.61%.

<i>Intra-day</i>			
<b>Day 0</b>			
Mean of concentration (mg/mL), n = 3	0.051	0.102	0.205
SD*	0.0004	0.0010	0.0015
RSD†	0.78	0.98	0.73
<b>Day 1</b>			
Mean of concentration (mg/mL), n = 3	0.055	0.104	0.202
SD	0.0005	0.0009	0.0019
RSD	0.91	0.87	0.94
<b>Day 2</b>			
Mean of concentration (mg/mL), n = 3	0.053	0.105	0.206
SD	0.0003	0.0006	0.0013
RSD	0.57	0.57	0.63
<i>Inter-day</i>			
Mean of concentrations of three days	0.053	0.104	0.204
SD	0.0004	0.0007	0.0016
RSD	0.76	0.67	0.78
* SD: standard deviation.			

*Precision*

The precision of the method was tested using six ( $n = 6$ ) injections of mirtazapine spiked with 0.5% (w/w) of each impurity, and the RSD of retention time ( $t_R$ ) and peak area were determined. The RSD ranged from 0.22 to 0.89%. The precision in determination of the assay was studied by repeatability, intermediate precision, and reproducibility (ruggedness). The RSD values were found to be below 1.0%, indicating a good repeatability (Table VII). The intermediate precision was calculated for three concentration levels using the data of 3 days and are expressed in terms of RSD

values (Table VII). At each concentration level, the RSD values were below 1.0%, indicating a good intermediate precision. The ruggedness of the method was studied by the analyzing the same samples under a variety of conditions at different labs, with different analysts using different instruments and different lots of reagents. The same samples at three concentrations were analyzed in triplicate on 2 days using another instrument (LC-10A Module HPLC system containing pump and UV-visible detector) by a different analyst with different lots of reagents and columns. The data obtained were within 2% RSD.

*Linearity, LOD, and LOQ*

The linearity of detector response to different concentrations of impurities was studied in the range from 0.5–5.0 µg/mL. Similarly, the linearity of mirtazapine was also studied by preparing standard solutions at ten different levels ranging from 25 to 200 µg/mL. The data were subjected to statistical analysis using a linear-regression model; the regression equations and coefficients ( $r^2$ ) are given in Table VIII. The results have indicated good linearity. LOD and LOQ were calculated as given in the “Experimental” section and the results are given in Table VIII. The LODs and LOQs were in the range 0.087%–0.131% and

0.252%–0.352% for mirtazapine.

**Table VIII. Calibration Data**

Sample	Range (µg/mL)	Regression equation	$r^2$	LOD (µg/mL)	LOQ (µg/mL)
I	0.5-5.0	$y = 16406x - 1075$	0.9979	0.087	0.279
II	0.5-5.0	$y = 36993x - 2486$	0.9962	0.083	0.252
III	0.5-5.0	$y = 30893x - 5287$	0.9941	0.090	0.265
IV	0.5-5.0	$y = 47795x + 1226$	0.9974	0.099	0.291
V	25-200	$y = 54441x + 141167$	0.9999	0.110	0.315
VI	0.5-5.0	$y = 37309x - 13918$	0.9960	0.131	0.352

**Table IX. Results of Analysis of Bulk Drugs and Formulations\***

Sample	(% Impurities (w/w))				
	I	II	III	IV	VI
Bulk-1	0.05	0.04	0.03	0.03	-
Bulk-2	0.03	0.05	-	-	0.03
Bulk-3	0.04	0.05	0.05	-	-
Form-1	-	0.06	0.03	0.05	-
Form-2	-	-	-	0.04	-
Form-3	-	0.05	-	-	-

\* Form: formulation; bulk: bulk drug.

**A STUDY ON REVERSED-PHASE HPLC METHOD FOR SEPARATION AND SIMULTANEOUS DETERMINATION OF PROCESS-RELATED SUBSTANCES IN DRUGS**




Figure 5. Overlay UV spectra of known impurities (I, II, III, IV and VI) and mirtazapine (V) (A), and unknown impurity (UK1) and excipients (EX1) (B).

**The results of analysis of bulk drugs and formulations**

High-low chromatographic technique was employed for detecting trace level impurities present in bulk drugs and formulations of mirtazapine. Accordingly, a very high concentration (1000 µg/mL) of formulation and bulk drug sample solutions were prepared as described in the “Experimental” section to increase the concentration of the impurities above their detection limits. The previously mentioned solutions were analyzed by the developed method and the results are recorded in Table IX. Almost all of the impurities were found in different amounts in all the formulations and bulk drugs studied. Unknown impurity UK1 and excipients (EX1) in the formulations were well-separated under the optimized conditions (Figure 4). The peaks were identified by injection and comparison with the retention times of the individual compounds, and also by the absorption spectra recorded by PDA detector (Figure 5). The assay for determining mirtazapine was carried out by diluting the previously mentioned solutions to 100 µg/mL with the mobile phase. The results of analysis of bulk drugs and formulations are given in Table X.

**Table X. Results of Analysis of Mirtazapine in Bulk Drugs and Formulations**

Sample	Concentration of mirtazapine			RSD
	Theoretical value (mg)	Found† value (mg)	(%) Recovery	
Bulk-1	15.23	15.28	100.33	0.35
Bulk-2	29.65	29.68	100.10	0.43
Bulk-3	30.51	30.32	99.38	0.27
Form-1	45.0	44.80	99.56	0.41
Form-2	30.0	30.22	100.73	0.52
Form-3	15.0	14.95	99.67	0.25

\* Form: formulation; bulk: bulk drug.  
† Average of three determinations.

## Conclusions

An isocratic RP-HPLC method has been developed and validated for determining the process-related substances and degradation products of mirtazapine in bulk drugs and pharmaceuticals. The separation of mirtazapine and its process-related impurities on different commercial C<sub>18</sub> columns was studied. The chromatographic conditions were optimized by studying the effects of temperature of the column, concentration of organic modifier, and concentration and pH of TEA buffer. The developed method was found to be selective, sensitive, precise, linear, accurate, and reproducible in determining mirtazapine and its potential impurities which may be present at trace levels in finished products. Thus, the method can be used for process development as well as quality assurance of mirtazapine in bulk drugs as well as pharmaceutical formulations.

## References

1. B.E. Leonard. Mirtazapine—Noradrenergic and specific serotonergic antidepressant (NaSSA). *Hum. Psychopharm.* **10(Suppl. 2)**: S81 (1995).
2. R. Davis and M.I. Wilde. Mirtazapine: A review of its

pharmacology and therapy potential in the management of major depression. *CNS Drugs* **5**: 389–402 (1996).

3. C.J. Timmer, A.A.M. Lohmann, and C.P.A. Mink. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron<sup>®</sup> tablets. *Hum. Psychopharm.* **10**: S97–S106 (1995).
4. L.P.C. Delpressine, M.E.G. Moonen, F.M. Kaspersen, G.N. Wagenaars, P.L. Jacobs, C.J. Timmer, J.E. Paanakker, H.J.M. van Hal, and G. Voortman. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. *Clin. Drug Invest.* **45–55** (1998).
5. L. Labat, M. Deveaux, P. Dallet, and J.P. Dubost. Separation of new antidepressants and their metabolites by micellar electrokinetic capillary chromatography. *J. Chromatogr. B* **773**: 17–23 (2002).
6. C. Sánchez De La Torre, M.A. Martínez, and E. Almarza. Determination of several psychiatric drugs in whole blood using capillary gas-liquid chromatography with nitrogen phosphorus detection: Comparison of two solid phase extraction procedures.

**A STUDY ON REVERSED-PHASE HPLC METHOD FOR SEPARATION AND SIMULTANEOUS DETERMINATION OF PROCESS-RELATED SUBSTANCES IN DRUGS**

7. *Forensic Sci. Int.* **155(2–3)**: 193–204 (2005) C.J. Timmer, J.E. Paanakker, and M. Vrijmoed-de Vries. Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. *Pharm. Res.* **14(1)**: 98–102 (1997).
8. C. Frahnert, M.L. Rao, and K. Grasmader. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: A simple tool for therapeutic drug monitoring. *J. Chromatogr. B* **794**: 35–47 (2003).
9. T. Romiguières, F. Pehourcq, M. Matoga, B. Begaud, and C. Jarry. Determination of mirtazapine and its demethyl metabolite in plasma by high-performance liquid chromatography with ultraviolet detection: Application to management of acute intoxication. *J. Chromatogr. B* **775**: 163–168 (2002).
10. K. Titier, N. Castaing, E. Scotto-Gomez, F. Perhourcq, N. Moore, and M. Molimard. High-performance liquid chromatographic method with diode array detection for identification and quantification of the eight new antidepressants and five of their active metabolites in plasma after overdose. *Ther. Drug Monit.* 581–587 (2003).
11. C. Duverneuil, Gl. de la Grandmaison, P. de Mazancourt, and J.C. Alvarez. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. *Ther. Drug Monit.* 565–573 (2003).
12. C. Pistos, M. Koutsopoulou, and I. Panderi. A validated liquid chromatographic tandem mass spectrometric method for the determination of mirtazapine and demethylmirtazapine in human plasma: Application to a pharmacokinetic study. *Anal. Chim. Acta* 15–26 (2004).
13. F.A. Maris, E. Dingler, and S.J. Niehues. High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma. *Chromatogr. B Biomed. Sci. Appl.* 309–316 (1999).
14. P.E. Morgan, J. Tapper, and E.P. Spencer. Measurement of total

- mirtazapine and normirtazapine in plasma/serum by liquid chromatography with fluorescence detection. *J. Chromatogr. B* **798(2)**: 211–215 (2003).
15. P. Ptacek, J. Klima, and J. Macek. Determination of mirtazapine in human plasma by liquid chromatography. *J. Chromatogr. B* **794 (2)**: 323–328 (2003).
16. S. Dodd, G.D. Burrows, and T.R. Norman. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. *J. Chromatogr. B* **748**: 439–443 (2000).
17. Z.D. Zhai, Y.P. Shi, and T. Wang. Development and validation of HPLC methods for enantioseparation of mirtazapine enantiomers at analytical and semipreparative scale using polysaccharide chiral stationary phases. *Anal. Chim. Acta* **550**: 123–129 (2005).
18. F.J. M. Santana, A.R.M. Oliveira, and P.S. Bonato. Chiral liquid chromatographic determination of mirtazapine in human plasma using two-phase liquid-phase microextraction for sample preparation. *Anal. Chim. Acta* **549**: 96–103 (2005).
19. N. Karasen and S. Altino. Determination of mirtazapine in tablets by UV spectrophotometric and derivative spectrophotometric methods. *J. Pharm. Biomed. Anal.* **24**: 11–17 (2000).
20. L. Labat, P. Dallet, E. Kummer, and J.P. Dubost. Spectrophotometric, spectrofluorimetric, HPLC and CZE determination of mirtazapine in pharmaceutical tablets. *J. Pharm. Biomed. Anal.* **28**: 365–371 (2002).
21. G.S. Wynia, G. Windhorst, P.C. Post, and F.A. Maris. Development and validation of a capillary electrophoresis method within a pharmaceutical quality control environment and comparison with high-performance liquid chromatography. *J. Chromatogr. A* **773**: 339–350 (1997).